Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SASHA COURTNEY DAVIS

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1194019075
CMS profile
2378874
Location
TYLER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$209.43

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $209.43 5

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Celgene Corporation $96.24 1
Novocure Inc. $60.43 1
Karyopharm Therapeutics Inc. $18.81 1
E.R. Squibb & Sons, L.L.C. $17.62 1
AbbVie Inc. $16.33 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SASHA COURTNEY DAVIS

NPI 1194019075 · CMS profile ID 2378874

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

TYLER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1194019075?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SASHA COURTNEY DAVIS, NPI 1194019075, CMS profile ID 2378874. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194019075?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). SASHA COURTNEY DAVIS, NPI 1194019075, CMS profile ID 2378874. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194019075?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
SASHA COURTNEY DAVIS, NPI 1194019075, CMS profile ID 2378874, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1194019075?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $209.43 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $16.3311/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722144487 CMS
Novocure Inc. $60.4309/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740699187 CMS
E.R. Squibb & Sons, L.L.C. $17.6208/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727787363 CMS
Karyopharm Therapeutics Inc. $18.8108/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751735349 CMS
Celgene Corporation $96.2402/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727787383 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $388.85 10
PY2020 $209.43 5
PY2021 $358.15 15
PY2022 $556.52 18
PY2023 $1,071.10 29
PY2024 $1,344.13 48
PY2025 $747.53 34

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $91,150.24 16
PY2024 Principal investigator $102,318.97 23
PY2023 Principal investigator $167,396.92 32
PY2022 Principal investigator $244,503.39 39
PY2021 Principal investigator $409,588.59 46
PY2020 Principal investigator $357,909.58 144
PY2019 Principal investigator $105,582.24 109

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

109 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $888.00 12/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691495217
Principal investigator 1 Merck Sharp & Dohme Corporation $1,560.50 11/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691491343
Principal investigator 1 Merck Sharp & Dohme Corporation $1,691.00 10/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691468329
Principal investigator 1 Merck Sharp & Dohme Corporation $680.00 10/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691487429
Principal investigator 1 Merck Sharp & Dohme Corporation $1,454.00 10/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691487551
Principal investigator 1 Merck Sharp & Dohme Corporation $1,280.00 10/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691495555
Principal investigator 1 Merck Sharp & Dohme Corporation $0.69 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691520755
Principal investigator 1 Merck Sharp & Dohme Corporation $1.11 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691521025
Principal investigator 1 Merck Sharp & Dohme Corporation $10.45 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691521031
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691521569
Principal investigator 1 Merck Sharp & Dohme Corporation $12.24 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691521575
Principal investigator 1 Merck Sharp & Dohme Corporation $12.98 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691521871
Principal investigator 1 Merck Sharp & Dohme Corporation $15.75 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691521873
Principal investigator 1 Merck Sharp & Dohme Corporation $17.60 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691521877
Principal investigator 1 Merck Sharp & Dohme Corporation $19.38 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691521881
Principal investigator 1 Merck Sharp & Dohme Corporation $19.80 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691522907
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691523243
Principal investigator 1 Merck Sharp & Dohme Corporation $205.20 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691523247
Principal investigator 1 Merck Sharp & Dohme Corporation $212.22 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691523253
Principal investigator 1 Merck Sharp & Dohme Corporation $23.60 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691523257
Principal investigator 1 Merck Sharp & Dohme Corporation $3.72 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691523261
Principal investigator 1 Merck Sharp & Dohme Corporation $0.27 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691524461
Principal investigator 1 Merck Sharp & Dohme Corporation $0.45 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691524465
Principal investigator 1 Merck Sharp & Dohme Corporation $0.45 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691524467
Principal investigator 1 Merck Sharp & Dohme Corporation $0.96 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691524471
Principal investigator 1 Merck Sharp & Dohme Corporation $30.92 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691524705
Principal investigator 1 Merck Sharp & Dohme Corporation $31.50 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691524709
Principal investigator 1 Merck Sharp & Dohme Corporation $35.16 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691524715
Principal investigator 1 Merck Sharp & Dohme Corporation $72.60 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691524719
Principal investigator 1 Merck Sharp & Dohme Corporation $72.60 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691524723
Principal investigator 1 Merck Sharp & Dohme Corporation $42.70 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691525043
Principal investigator 1 Merck Sharp & Dohme Corporation $6.84 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691525049
Principal investigator 1 Merck Sharp & Dohme Corporation $65.89 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691525695
Principal investigator 1 Merck Sharp & Dohme Corporation $0.27 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691526147
Principal investigator 1 Merck Sharp & Dohme Corporation $35.16 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691538905
Principal investigator 1 Merck Sharp & Dohme Corporation $13.44 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691539411
Principal investigator 1 Merck Sharp & Dohme Corporation $21.83 10/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691539415
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 09/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691331611
Principal investigator 1 Merck Sharp & Dohme Corporation $36.00 09/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691331868
Principal investigator 1 Merck Sharp & Dohme Corporation $264.00 09/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691331901
Principal investigator 1 Merck Sharp & Dohme Corporation $460.00 09/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691332535
Principal investigator 1 Merck Sharp & Dohme Corporation $235.00 09/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691332710
Principal investigator 1 Merck Sharp & Dohme Corporation $595.00 09/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691333055
Principal investigator 1 Merck Sharp & Dohme Corporation $60.00 09/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691364947
Principal investigator 1 Merck Sharp & Dohme Corporation $1,953.00 09/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691364983
Principal investigator 1 Merck Sharp & Dohme Corporation $80.00 09/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691365027
Principal investigator 1 Merck Sharp & Dohme Corporation $150.00 09/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691366805
Principal investigator 1 Merck Sharp & Dohme Corporation $47.16 09/10/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691376845
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 09/10/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691377807
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 09/10/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691404635
Principal investigator 1 Merck Sharp & Dohme Corporation $12.20 09/10/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691404639
Principal investigator 1 Merck Sharp & Dohme Corporation $24.20 09/10/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691404987
Principal investigator 1 Merck Sharp & Dohme Corporation $3.84 09/10/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691404991
Principal investigator 1 Merck Sharp & Dohme Corporation $45.60 09/10/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691405163
Principal investigator 1 Merck Sharp & Dohme Corporation $1.76 09/10/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691405415
Principal investigator 1 Merck Sharp & Dohme Corporation $21,652.48 08/29/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691448559
Principal investigator 1 Merck Sharp & Dohme Corporation $595.00 08/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691331981
Principal investigator 1 Merck Sharp & Dohme Corporation $1,295.00 08/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691332901
Principal investigator 1 Merck Sharp & Dohme Corporation $1,530.00 08/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691363873
Principal investigator 1 Merck Sharp & Dohme Corporation $595.00 08/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691364871
Principal investigator 1 Merck Sharp & Dohme Corporation $595.00 08/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691364943
Principal investigator 1 Merck Sharp & Dohme Corporation $32,478.72 08/09/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691456787
Principal investigator 1 Merck Sharp & Dohme Corporation $21.83 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691376179
Principal investigator 1 Merck Sharp & Dohme Corporation $3.72 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691376183
Principal investigator 1 Merck Sharp & Dohme Corporation $35.16 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691376843
Principal investigator 1 Merck Sharp & Dohme Corporation $0.27 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691377197
Principal investigator 1 Merck Sharp & Dohme Corporation $0.96 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691377257
Principal investigator 1 Merck Sharp & Dohme Corporation $15.75 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691377305
Principal investigator 1 Merck Sharp & Dohme Corporation $19.80 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691377307
Principal investigator 1 Merck Sharp & Dohme Corporation $0.27 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691394259
Principal investigator 1 Merck Sharp & Dohme Corporation $0.45 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691394263
Principal investigator 1 Merck Sharp & Dohme Corporation $0.45 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691394265
Principal investigator 1 Merck Sharp & Dohme Corporation $0.69 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691394271
Principal investigator 1 Merck Sharp & Dohme Corporation $30.92 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691402873
Principal investigator 1 Merck Sharp & Dohme Corporation $31.50 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691402878
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691404039
Principal investigator 1 Merck Sharp & Dohme Corporation $205.20 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691404044
Principal investigator 1 Merck Sharp & Dohme Corporation $212.22 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691404047
Principal investigator 1 Merck Sharp & Dohme Corporation $35.16 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691404055
Principal investigator 1 Merck Sharp & Dohme Corporation $42.70 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691404059
Principal investigator 1 Merck Sharp & Dohme Corporation $65.89 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691404551
Principal investigator 1 Merck Sharp & Dohme Corporation $72.60 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691404627
Principal investigator 1 Merck Sharp & Dohme Corporation $72.60 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691404631
Principal investigator 1 Merck Sharp & Dohme Corporation $12.24 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691404809
Principal investigator 1 Merck Sharp & Dohme Corporation $12.98 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691404813
Principal investigator 1 Merck Sharp & Dohme Corporation $13.44 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691404891
Principal investigator 1 Merck Sharp & Dohme Corporation $17.60 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691404895
Principal investigator 1 Merck Sharp & Dohme Corporation $19.38 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691404899
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691404903
Principal investigator 1 Merck Sharp & Dohme Corporation $23.60 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691404983
Principal investigator 1 Merck Sharp & Dohme Corporation $6.84 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691405167
Principal investigator 1 Merck Sharp & Dohme Corporation $1.11 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691405349
Principal investigator 1 Merck Sharp & Dohme Corporation $10.45 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691405419
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 08/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691405423
Principal investigator 1 Merck Sharp & Dohme Corporation $595.00 07/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691332139
Principal investigator 1 Merck Sharp & Dohme Corporation $595.00 07/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691332143
Principal investigator 1 Merck Sharp & Dohme Corporation $595.00 07/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691332977
Principal investigator 1 Merck Sharp & Dohme Corporation $1,455.00 07/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691333779
Principal investigator 1 Merck Sharp & Dohme Corporation $680.00 07/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691365237
Principal investigator 1 Merck Sharp & Dohme Corporation $15.00 06/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691303127
Principal investigator 1 Merck Sharp & Dohme Corporation $25.50 06/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691303173
Principal investigator 1 Merck Sharp & Dohme Corporation $2,092.00 06/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691303297
Principal investigator 1 Merck Sharp & Dohme Corporation $595.00 06/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691304151
Principal investigator 1 Merck Sharp & Dohme Corporation $80.00 06/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691304457
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 06/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691305739
Principal investigator 1 Merck Sharp & Dohme Corporation $1,714.00 06/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691306299
Principal investigator 1 Merck Sharp & Dohme Corporation $17.40 04/10/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691344177
Principal investigator 1 Merck Sharp & Dohme Corporation $7,999.00 02/15/2019 Non-covered Recipient Entity
NORTHWEST CANCER SPECIALISTS, P.C.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691289433
Principal investigator 1 Merck Sharp & Dohme Corporation $16,246.14 01/29/2019 Non-covered Recipient Entity
US ONCOLOGY AND RESEARCH
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 691539541